The role of pharmaceutical nanotechnology in the time of COVID-19 pandemic

Future Microbiol. 2020 Oct:15:1571-1582. doi: 10.2217/fmb-2020-0118. Epub 2020 Nov 20.

Abstract

There is no effective therapy against COVID-19 available so far. In the last months, different drugs have been tested as potential treatments for COVID-19, exhibiting high toxicity and low efficacy. Therefore, nanotechnology can be applied to improve the therapeutic action and minimize the toxicity of loaded drugs. In this review, we summarized the drugs tested as COVID-19 treatment and the advantages of antiviral nanostructured drug-delivery systems. Such systems have demonstrated low in vitro toxicity with better in vitro antiviral activity than free drugs. We believe that this approach should inspire novel nanostructured drug-delivery systems developments to find efficient COVID-19 treatments. Here, we discuss the remaining challenges for such promising nanosystems to be approved for clinical use.

Keywords: COVID-19; drug toxicity; nanostructured delivery systems; nanotechnology.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • COVID-19 Drug Treatment*
  • Clinical Trials as Topic
  • Drug Compounding
  • Drug Delivery Systems*
  • Humans
  • Mice
  • Middle East Respiratory Syndrome Coronavirus / drug effects
  • Nanostructures
  • Nanotechnology / methods*
  • SARS-CoV-2 / drug effects
  • Severe acute respiratory syndrome-related coronavirus / drug effects

Substances

  • Antiviral Agents